What Amgen’s Recent Share Moves Signal for Investors
Amgen (AMGN) has seen mixed recent returns, with gains over the past year but a decline over the past month. This performance is prompting investors to reassess how the current share price lines up with fundamentals.
See our latest analysis for Amgen.
Recent trading has been choppy, with a 7.76% 1 month share price decline. However, the 90 day share price return of 6.08% and 1 year total shareholder return of 19.12% point to momentum that has mostly held up over a longer stretch.
If Amgen’s recent moves have you thinking about what else is happening across healthcare, this is a good moment to scan for other potential opportunities in 36 healthcare AI stocks
With Amgen trading near its analyst price target yet showing a 46% intrinsic discount, the key question is whether the market is overlooking its fundamentals or has already factored in much of its future growth potential.
Most Popular Narrative: 1% Overvalued
Amgen’s most followed valuation narrative pegs fair value at $350.03, slightly below the recent $353.16 close, which frames a very tight gap between price and fundamentals.
Advancements in personalized and targeted therapies, reflected in the robust late-stage pipeline (for example, MariTide for obesity/type 2 diabetes, Repatha and olpasiran for cardiovascular, multiple bispecific T-cell engagers for oncology), position Amgen to launch high-margin, first-in-class products that drive both top-line growth and margin expansion in the coming years.
Read the complete narrative. Read the complete narrative.
Curious what earnings trajectory, margin lift, and future P/E multiple are baked into that fair value line that almost meets today’s price? The underlying model leans on steady top line assumptions, fatter profitability, and a richer earnings multiple than the broader biotech space. The tension lies in how much of that future profile is already embedded in the current share price, and how much is still being debated in analyst models.
Result: Fair Value of $350.03 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still pressure points to keep in mind, including drug pricing reforms and biosimilar competition, which could weigh on revenue and margins.
Find out about the key risks to this Amgen narrative.
Another Way to Look at Amgen’s Value
While the narrative-based fair value of $350.03 suggests Amgen is roughly in line with its recent $353.16 price, the SWS DCF model paints a very different picture, with a future cash flow value of $655.34 that frames the shares as heavily undervalued. Which story do you put more weight on?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
Mixed signals or a clear message, either way this is the moment to look through the numbers yourself and decide how you feel about Amgen’s risk and reward trade off with 4 key rewards and 1 important warning sign
Looking for more investment ideas?
If Amgen has sharpened your focus, do not stop here. Casting a wider net with a few targeted stock ideas can round out your watchlist fast.
- Zero in on value by scanning 61 high quality undervalued stocks that combine solid fundamentals with a price that may not fully reflect their underlying strength.
- Strengthen your income potential by reviewing 12 dividend fortresses built around higher yielding payouts that may interest dividend focused investors.
- Dial back portfolio risk by checking 69 resilient stocks with low risk scores that score well on stability and downside resilience.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com